GALLIUM: GAZYVA vs rituximab product Is the Largest 1L FL Study Ever
Conducted
This Phase III, open-label, randomized trial was designed to answer one primary question: In patients with previously untreated FL, did the GAZYVA (obinutuzumab) based regimen deliver superior PFS compared with the rituximab product-based regimen? 1
The GALLIUM trial studied patients with previously untreated follicular lymphoma (Grades 1-3a, stage III/IV or stage II bulky disease [≥7 cm])
- Primary endpoint: PFS as assessed by Independent Review Committee (IRC)
-
Additional endpoint: Response rates at end of induction
(IRC-assessed, assessed by CT)